Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Share-based Compensation data on file, last reported at $37.8 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 1104.59% year-over-year to $37.8 million; the trailing twelve-month figure through Dec 2025 stood at $37.8 million (up 795.95% YoY), and the FY2025 full-year result was $17.4 million, up 1999.52% from the prior year.
• Share-based Compensation rose to $37.8 million in Q4 2025, from $5.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $37.8 million in Q4 2025 to a low of -$92000.0 in Q1 2022.
• A 5-year average of $3.3 million and a median of $275000.0 in 2021 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 139.15% in 2022 and surged 3274.19% in 2024, its largest moves.
• Tracing BNTC's Share-based Compensation over 5 years: stood at $523000.0 in 2021, then slumped by 109.18% to -$48000.0 in 2022, then jumped by 293.75% to $93000.0 in 2023, then surged by 3274.19% to $3.1 million in 2024, then soared by 1104.59% to $37.8 million in 2025.
• Business Quant data shows BNTC's Share-based Compensation at $37.8 million in Q4 2025, $5.2 million in Q3 2025, and $13.5 million in Q2 2025.